ALFA Finder| Revenue growth | 13.8% YoY; partly inorganic via Oclutech consolidation. |
|---|---|
| Margins | EBITDA 22.5%; FY27 likely near FY26's 20.4%; Oclutech ~80bps drag. |
| Demand visibility | India growth in line with IPM; Chronic 22.4% vs 16% industry. |
| Management confidence | Balanced; declined margin guidance raise, cut US outlook to mid-single digit. |
Growth
Revenue +13.8% includes Oclutech consolidation from mid-July. Chronic +22.4% vs IPM 16%; acute in line with market.
Outlook
FY27 US growth mid-single-digit in constant currency; margin near FY26's 20.4%. Enzene ₹300–350 Cr, MedTech ~₹400 Cr capex over 3–4 years.
Risks
Daman OAI status delays ~8 products due in 6–12 months. Denosumab biosimilar BLA setback, trade-generic price pressure, and PAT decline.
Last quarter's promises, checked
Delivered
- Tolvaptan US launch in Q2 → launched Sept (= BEAT)
Missed
- US FY27 growth high-single to mid CC → cut to mid-single; Q2 US CC −3% (= MISS)
- Daman OAI no FY27 business impact, recovery in 6–12 mo → ~8 products delayed 6–12 mo (= MISS)
- US price erosion 'close to flattish, bottomed out' → ~16% erosion (= MISS)
Earnings Call Transcript filed with NSE, NSE: ALKEM. Summary written with AI assistance from the document.
Alkem Laboratories Ltd: key numbers
- Share price
- ₹5,114.00
- Market cap
- ₹61,146 Cr
- Revenue (annual)
- ₹14,712 Cr
- Net profit (annual)
- ₹2,302 Cr
- P/E (TTM)
- 29.6×Sector 43.7×
- Promoter holding
- 49.70%+0.00% QoQ
- FII holding
- 10.32%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Alkem Laboratories Ltd
All →Alkem Laboratories Results Update
Alkem posted Q2FY27 revenue of ₹4,552 Cr, up 14% YoY, with 22.5% EBITDA margin. Net profit fell 11.7% to ₹675 Cr on higher R&D.
Alkem Laboratories Management Change
Alkem Laboratories appointed Mr. Gopal Kothari as CFO and Key Managerial Personnel effective 2 December 2026. The 24-year finance veteran is a CA and CS.
Alkem Laboratories Q2 FY27 Results: Net Profit ₹667.1 Cr, Down 14.4% YoY
Alkem Laboratories Ltd reported revenue from operations of ₹4,552 Cr (+13.8% YoY) and net profit of ₹667.1 Cr (-14.4% YoY) for Q2 FY27.
- Key figure
- Net profit ₹667.1 Cr · -14.4% YoY
Alkem Laboratories Merger & Restructuring Worth ₹9.56 Cr
Alkem incorporated a Saudi Arabian joint venture subsidiary, Alkem Pharma Company LLC, on 8 November 2026. It holds 51% after subscribing SAR 38.25 lakh, about ₹9.56 Crore.
- Value
- ₹9.56 Cr
Alkem Laboratories Board Meeting Date
Alkem Laboratories has scheduled its Board meeting for 12 Nov 2026 to consider Q2 and H1 FY27 unaudited results. No financial figures are disclosed in this advance notice.
Alkem Laboratories Management Change
Alkem Laboratories appointed Dr. Amrut Naik as CEO effective November 11, 2026. The Board designated him as Key Managerial Personnel at its November 3 meeting.